Comparative Analysis of Neoadjuvant Immunochemotherapy and Neoadjuvant Targeted Therapy Combined with Chemotherapy in Patients with EGFR-Mutated Non-Small Cell Lung Cancer: A Retrospective Investigation - Takeaways - MDSpire

Comparative Analysis of Neoadjuvant Immunochemotherapy and Neoadjuvant Targeted Therapy Combined with Chemotherapy in Patients with EGFR-Mutated Non-Small Cell Lung Cancer: A Retrospective Investigation

  • By

  • Feng Li

  • Chaoqi Zhang

  • Luyu Huang

  • Ziming Wang

  • Guanchao Ye

  • Zhuoyu Gu

  • Yu Qi

  • January 20, 2026

  • 0 min

Share

  • 1

    Approximately 30% of non-small cell lung cancer patients have EGFR mutations, impacting treatment strategies.

  • 2

    Neoadjuvant chemotherapy is the current standard for EGFR-mutated NSCLC, but it often yields poor pathologic response outcomes.

  • 3

    Recent studies suggest that neoadjuvant immunochemotherapy may improve outcomes compared to traditional chemotherapy.

  • 4

    This study compares the effectiveness of neoadjuvant immunochemotherapy and targeted therapy combined with chemotherapy.

  • 5

    A total of 89 patients with EGFR-mutated NSCLC were analyzed, focusing on surgical outcomes following neoadjuvant therapy.

Original Source(s)

Comparative Analysis of Neoadjuvant Immunochemotherapy and Neoadjuvant Targeted Therapy Combined with Chemotherapy in Patients with EGFR-Mutated Non-Small Cell Lung Cancer: A Retrospective Investigation

  • by Feng Li, Chaoqi Zhang, Luyu Huang, Ziming Wang, Guanchao Ye, Zhuoyu Gu, Yu Qi

  • January 20, 2026

Related Content

Percutaneous nephrostomy as a marker of clinical vulnerability in non-metastatic muscle-invasive bladder cancer: prognostic and infectious implications

Stimuli-responsive nanoplatforms for sonodynamic immunotherapy: opportunities and challenges in cancer treatment

Ultra-high-sensitivity next-generation sequencing–based MRD predicts outcome in intensively treated older patients with acute myeloid leukemia: results from the ALFA-1200 cohort